ALXN News and Press, Alexion Pharmaceuticals Inc. From 04/24/19

Mustang Bio, Inc. ( MBIO ) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, ...

Yes, it shrinks As you know, healthcare stocks and ETFs, such as the Health Care Select SPDR ETF ( XLV ), have gotten slammed following additional publicity given just a few days ago to Senator Bernie Sanders and his "Medicare for all" ((MFA)) program. Before the political season began this ...

Investors in biotechs and biopharma firms appear to have intensified their profit-taking after the Q1 run-up, stoked, no doubt, from the sour mood in Congress over high drug prices and the Trump administration's stated priority to tackle the problem. More news on: SPDR Biotech ETF, SPDR S&...

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2019 before the US financial markets open on April 25, 2019. Following the release of the financial results, Alexion management will conduct a...

Alexion Pharmaceuticals (NASDAQ: ALXN ) resumed with Outperform rating and $161 (17% upside) price target at Raymond James. More news on: Alexion Pharmaceuticals, Inc., Biogen Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

In a recent StockWaves webinar, we examined the IBD 50 using the Innovator IBD 50 Fund ( FFTY ) ETF. This can be a good instrument to use to examine momentum, because of the way Investor's Business Daily selects their list targeting names they feel are generating outstanding profit growth, big...

The U.S. Department of Justice has reached agreement with Jazz Pharmaceuticals ( JAZZ +1.3% ), Alexion Pharmaceuticals ( ALXN -0.2% ) and Lundbeck, LLC to resolve allegations that they illegally paid Medicare or Civilian Health and Medical Program copays for their own products through ...

Prologue Since we mentioned it for the first time four months ago , the US yield curve has inverted further, raising fresh concerns about the risk of an upcoming recession . There are arguments to be made that "this time is different” in interpreting inversion. However, there is...

At $508,000 per patient per year, Alexion Pharmaceuticals' ( ALXN ) Soliris (eculizumab) is the most expensive drug in the world. There have been many efforts to replicate the efficacy of the most expensive drug in the world without that high price tag. These efforts have taken the forms of ha...

(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...